PMID- 37955633
OWN - NLM
STAT- MEDLINE
DCOM- 20240304
LR  - 20240313
IS  - 1205-7541 (Electronic)
IS  - 0008-4212 (Linking)
VI  - 102
IP  - 3
DP  - 2024 Mar 1
TI  - TLR/mTOR inflammatory signaling pathway: novel insight for the treatment of 
      schizophrenia.
PG  - 150-160
LID - 10.1139/cjpp-2023-0107 [doi]
AB  - The Toll-like receptor (TLR)/mammalian target of rapamycin (mTOR) signaling 
      pathway is involved in the intracellular regulation of protein synthesis, 
      specifically the ones that mediate neuronal morphology and facilitate synaptic 
      plasticity. The activity of TLR/mTOR signaling has been disrupted, leading to 
      neurodevelopment and deficient synaptic plasticity, which are the main symptoms 
      of schizophrenia. The TLR receptor activates the mTOR signaling pathway and 
      increases the elevation of inflammatory cytokines. Interleukin (IL)-6 is the most 
      commonly altered cytokine, while IL-1, tumor necrosis factor, and interferon 
      (IFN) also lead to SCZ. Anti-inflammatory and anti-oxidative agents such as 
      celecoxib, aspirin, minocycline, and omega-3 fatty acids have shown efficiency 
      against SCZ. As a result, inhibition of the inflammatory process could be 
      suggested for the treatment of SCZ. So mTOR/TLR blockers represent the treatment 
      of SCZ due to their inflammatory consequences. The objective of the present work 
      was to find a novel anti-inflammatory agent that may block the mTOR/TLR 
      inflammatory signaling pathways and might pave the way for the treatment of 
      neuroinflammatory SCZ. Data were collected from experimental and clinical studies 
      published in English between 1998 and October 2022 from Google Scholar, PubMed, 
      Scopus, and the Cochrane library.
FAU - Lashgari, Naser-Aldin
AU  - Lashgari NA
AUID- ORCID: 0000-0003-0502-6114
AD  - Department of Toxicology & Pharmacology, Faculty of Pharmacy, Tehran Medical 
      Sciences, Islamic Azad University, Tehran, Iran.
AD  - GI Pharmacology Interest Group (GPIG), Universal Scientific Education and 
      Research Network (USERN), Tehran, Iran.
FAU - Roudsari, Nazanin Momeni
AU  - Roudsari NM
AUID- ORCID: 0000-0003-1230-7969
AD  - Department of Toxicology & Pharmacology, Faculty of Pharmacy, Tehran Medical 
      Sciences, Islamic Azad University, Tehran, Iran.
AD  - GI Pharmacology Interest Group (GPIG), Universal Scientific Education and 
      Research Network (USERN), Tehran, Iran.
FAU - Shamsnia, Hedieh Sadat
AU  - Shamsnia HS
AUID- ORCID: 0000-0002-7309-033X
AD  - Department of Toxicology & Pharmacology, Faculty of Pharmacy, Tehran Medical 
      Sciences, Islamic Azad University, Tehran, Iran.
AD  - GI Pharmacology Interest Group (GPIG), Universal Scientific Education and 
      Research Network (USERN), Tehran, Iran.
FAU - Shayan, Maryam
AU  - Shayan M
AUID- ORCID: 0000-0001-6881-3436
AD  - Department of Pharmacology, School of Medicine, Tehran University of Medical 
      Sciences, Tehran, Iran.
AD  - Experimental Medicine Research Center, Tehran University of Medical Sciences, 
      Tehran, Iran.
FAU - Momtaz, Saeideh
AU  - Momtaz S
AUID- ORCID: 0000-0003-3957-3300
AD  - Medicinal Plants Research Center, Institute of Medicinal Plants, The Academic 
      Center for Education, Culture and Research (ACECR), Karaj, Iran.
AD  - Toxicology and Diseases Group (TDG), Pharmaceutical Sciences Research Center 
      (PSRC), The Institute of Pharmaceutical Sciences (TIPS), and Faculty of Pharmacy, 
      Tehran University of Medical Sciences, Tehran, Iran.
FAU - Abdolghaffari, Amir Hossein
AU  - Abdolghaffari AH
AUID- ORCID: 0000-0001-9961-9097
AD  - Department of Toxicology & Pharmacology, Faculty of Pharmacy, Tehran Medical 
      Sciences, Islamic Azad University, Tehran, Iran.
AD  - GI Pharmacology Interest Group (GPIG), Universal Scientific Education and 
      Research Network (USERN), Tehran, Iran.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20231113
PL  - Canada
TA  - Can J Physiol Pharmacol
JT  - Canadian journal of physiology and pharmacology
JID - 0372712
RN  - R16CO5Y76E (Aspirin)
RN  - 0 (Cytokines)
RN  - 0 (Interleukin-6)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
RN  - EC 2.7.1.1 (MTOR protein, human)
SB  - IM
MH  - Humans
MH  - Aspirin
MH  - Cytokines
MH  - Interleukin-6
MH  - *Schizophrenia/drug therapy
MH  - Signal Transduction
MH  - TOR Serine-Threonine Kinases
OTO - NOTNLM
OT  - Toll-like receptor (TLR)
OT  - mammalian target of rapamycin (mTOR)
OT  - neuroinflammation
OT  - schizophrenia
COIS- The authors have no relevant financial or non-financial interests to disclose.
EDAT- 2023/11/13 12:44
MHDA- 2024/03/04 06:45
CRDT- 2023/11/13 10:43
PHST- 2024/03/04 06:45 [medline]
PHST- 2023/11/13 12:44 [pubmed]
PHST- 2023/11/13 10:43 [entrez]
AID - 10.1139/cjpp-2023-0107 [doi]
PST - ppublish
SO  - Can J Physiol Pharmacol. 2024 Mar 1;102(3):150-160. doi: 10.1139/cjpp-2023-0107. 
      Epub 2023 Nov 13.